KKRC
ASBPW

Kohlberg Kravis Roberts & Co’s Aspire Biopharma Warrant ASBPW Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,273
Closed -$3K – 135
2022
Q3 		$3K Sell
25,273
-12,227
-33% -$1.78K ﹤0.01% 196
2022
Q2 		$6K Buy
+37,500
New +$8.16K ﹤0.01% 229

Other funds holding ASBPW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's ASBPW Position: Q4 2022 in Review

Kohlberg Kravis Roberts & Co sold out of Aspire Biopharma Warrant (ASBPW) in Q4 2022, closing a stake of 25,273 shares — an estimated $3K sold.

Kohlberg Kravis Roberts & Co first reported a position in ASBPW in Q2 2022 and held it in 2 quarters. The position peaked at $6K in Q2 2022. 36 funds tracked by Wall St. Rank hold ASBPW as of Q4 2022.

  • Kohlberg Kravis Roberts & Co reported no remaining Aspire Biopharma Warrant position as of Q4 2022 after selling out during the quarter.
  • Kohlberg Kravis Roberts & Co sold 25,273 Aspire Biopharma Warrant shares in Q4 2022, an estimated $3K.
  • Kohlberg Kravis Roberts & Co first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 2 quarters.
  • Kohlberg Kravis Roberts & Co's Aspire Biopharma Warrant position peaked at $6K in Q2 2022.
  • 36 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q4 2022.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q4 2022, filed 14 Feb 2023.